BioGeometry raises $100M in Series A extension for its AI drug-design models
What's the deal? Beijing-based AI-native biopharma company BioGeometry has closed a Series A extension, bringing its total Series A funding above $100 million. China Life Capital led the round, with Shanghai Biopharmaceutical Fund re-upping and CDB KechuangDealroom has a profile for this one. Try Dealroom →, Fortune CapitalDealroom has a profile for this one. Try Dealroom →, Guofang CapitalDealroom has a profile for this one. Try Dealroom →, and Ruili Investment joining.
What's the endgame? The company uses generative AI to build what it calls "micro-world models" of biology — GeoFlow at the molecular level and GeoCell at the cellular level — to design antibodies, vaccines, peptides, and enzymes. It pairs these models with automated labs in a dry-wet feedback loop meant to let the system improve as it runs.
Where's the money going? BioGeometry plans to spend the funds on iterating both models, expanding its high-throughput automated labs, and advancing its own drug pipeline toward commercialisation. It says several bispecific antibody programs are slated to enter clinical trials in 2027.
Why now? The raise lands as Chinese AI-drug-discovery funding heats up and concentrates on top projects. Public reports indicate the sector raised more in the first nine months of 2026 than in any full year from 2023 to 2025, with a handful of large deals taking a sizeable share.
What could go wrong? The real test is whether the models produce reproducible drug candidates and clinical progress, not just designs. Key technical metrics such as hit rates come mainly from the company's own disclosures, so they warrant caution.
China Life Capital said scientific AI is "a core engine driving a shift in research paradigms," framing the bet as a move on AI reshaping global life-sciences R&D.
The signal: BioGeometry's round shows capital flowing to a narrow set of prominent AI-drug players in China, where investors are wagering that foundation-model approaches can compress discovery timelines. Whether that translates into approved therapies remains the open question.
Read more: sohu.com
Image credit: Generated with Gemini
